- Home
- LRMR vs CLLS Comparison
LRMR vs CLLS Comparison
Compare LRMR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LRMR | CLLS |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 394.4M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LRMR | CLLS |
|---|---|---|
| Price | $4.07 | $3.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $16.50 | $8.33 |
| AVG Volume (30 Days) | ★ 1.2M | 14.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,816.14 | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $2.35 |
| 52 Week High | $6.42 | $5.48 |
Technical Indicators
Market Signals| Indicator | LRMR | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 55.02 |
| Support Level | $2.98 | $3.00 |
| Resistance Level | $4.21 | $3.40 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 58.96 | 82.53 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.